FDA Approves Obstructive Sleep Apnoea Neurostim

Image credit: Kinga Howard via Unsplash

A neurostimulation device for treating obstructive sleep apnoea has been the greenlight from the US Food and Drug Administration (FDA).

US-based Inspire Medical Systems’ Inspire V device includes a neurostimulator that sends gentle electrical stimulation to the hypoglossal nerve – responsible for controlling the tongue muscles – together with a Bluetooth-enabled patient remote and a clinician programmer.

“We are thrilled to announce the FDA approval of our next generation Inspire neurostimulation system,” said Inspire Medical Systems Chairman and Chief Executive Officer, Tim Herbert in a statement.

“The FDA approval marks a key milestone for the future of Inspire therapy and reinforces the many years of hard work by our team members.”

A soft launch of the device is set for later this year, followed by a full launch in 2025.

Check out the full press release via Inspire Medical Systems for more details, or watch the quick clip below to see the technology in action.